For instance, PD-L1, a renowned biomarker of response to immunotherapy in other solid tumors, has been reported in 9–70% of the cases in CCA but its association with patient-relevant outcomes remains unclear [61,62,63,64,65]. Here, CD274 is linked to cholangiocarcinoma.